Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a ...

Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive ...

In a June 24, 2025, podcast, Goldman Sachs’ Christian Mueller-Glissmann and Alexandra Wilson-Elizondo examined the dynamics ...

Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised ...

Health news includes a cyberattack affecting patient care in London, Walgreens' financial success amid strategic changes, Pfizer's trial success, Altimmune's setback, Eli Lilly's competitive launch in ...

Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver scarring in patients with fatty liver disease in a mid-stage trial.

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis ...

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis during a key MASH trial. While it helped with MASH resolution and weight ...